| Primary |
| Asthma |
46.6% |
| Product Used For Unknown Indication |
21.2% |
| Chronic Obstructive Pulmonary Disease |
10.9% |
| Emphysema |
4.3% |
| Hypertension |
4.0% |
| Pulmonary Fibrosis |
2.7% |
| Bronchitis Chronic |
1.2% |
| Bronchitis |
1.0% |
| Prophylaxis |
1.0% |
| Arrhythmia |
0.9% |
| Angina Pectoris |
0.8% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Nervous System Disorder |
0.8% |
| Osteoporosis |
0.6% |
| Analgesic Asthma Syndrome |
0.5% |
| Bronchiectasis |
0.5% |
| Epilepsy |
0.5% |
| Insomnia |
0.5% |
| Respiratory Tract Infection |
0.5% |
| Rhinitis Allergic |
0.5% |
|
| Death |
18.6% |
| Asthma |
16.0% |
| Product Quality Issue |
16.0% |
| Drug Ineffective |
8.2% |
| Dysphonia |
4.3% |
| Cough |
3.5% |
| Oesophageal Candidiasis |
3.5% |
| Pneumonia |
3.5% |
| Dyspnoea |
3.0% |
| Pulmonary Fibrosis |
3.0% |
| Oral Candidiasis |
2.6% |
| Overdose |
2.6% |
| Asthmatic Crisis |
2.2% |
| Burning Sensation |
2.2% |
| Pyrexia |
2.2% |
| Acute Myocardial Infarction |
1.7% |
| Bronchitis |
1.7% |
| Headache |
1.7% |
| Neoplasm Malignant |
1.7% |
| Osteonecrosis |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
46.9% |
| Asthma |
27.1% |
| Chronic Obstructive Pulmonary Disease |
9.2% |
| Respiratory Tract Infection |
3.5% |
| Atrial Fibrillation |
1.6% |
| Hypertension |
1.5% |
| Pyrexia |
1.2% |
| Bronchitis Chronic |
1.0% |
| Hypersensitivity |
1.0% |
| Prophylaxis |
0.9% |
| Respiratory Arrest |
0.9% |
| Hypercholesterolaemia |
0.7% |
| Mental Disorder |
0.7% |
| Pulmonary Arterial Hypertension |
0.7% |
| Depression |
0.6% |
| Anxiety Disorder |
0.5% |
| Cardiac Disorder |
0.5% |
| Maternal Exposure During Pregnancy |
0.5% |
| Panic Disorder |
0.5% |
| Rheumatoid Arthritis |
0.5% |
|
| Asthma |
15.2% |
| Drug Ineffective |
8.7% |
| Dyspnoea |
6.5% |
| Transient Ischaemic Attack |
6.5% |
| Adrenal Insufficiency |
5.4% |
| Oral Candidiasis |
5.4% |
| Chest Pain |
4.3% |
| Death |
4.3% |
| Hypotension |
4.3% |
| Poisoning |
4.3% |
| Respiratory Tract Infection Fungal |
4.3% |
| Toxicity To Various Agents |
4.3% |
| Abdominal Pain Upper |
3.3% |
| Acth Stimulation Test Abnormal |
3.3% |
| Acute Myocardial Infarction |
3.3% |
| Asthenia |
3.3% |
| Chronic Obstructive Pulmonary Disease |
3.3% |
| Depression |
3.3% |
| Dysphonia |
3.3% |
| Hemiparesis |
3.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.0% |
| Asthma |
12.9% |
| Chronic Obstructive Pulmonary Disease |
11.5% |
| Hypertension |
6.0% |
| Pain |
3.4% |
| Atrial Fibrillation |
2.8% |
| Prophylaxis |
2.5% |
| Osteoporosis |
2.2% |
| Depression |
2.1% |
| Diabetes Mellitus |
1.8% |
| Rheumatoid Arthritis |
1.7% |
| Hepatitis C |
1.5% |
| Non-small Cell Lung Cancer |
1.5% |
| Behcet's Syndrome |
1.4% |
| Breast Cancer |
1.4% |
| Mental Disorder |
1.1% |
| Multiple Myeloma |
1.1% |
| Dyspnoea |
1.1% |
| Bronchitis |
0.9% |
| Gastrooesophageal Reflux Disease |
0.9% |
|
| Asthma |
12.9% |
| Death |
7.1% |
| Chronic Obstructive Pulmonary Disease |
6.7% |
| Dyspnoea |
6.3% |
| Cardiac Arrest |
5.8% |
| Renal Failure Acute |
5.8% |
| Abdominal Pain Upper |
4.9% |
| Diarrhoea |
4.9% |
| Pneumonia |
4.9% |
| Cerebrovascular Accident |
4.5% |
| General Physical Health Deterioration |
4.0% |
| Pyrexia |
4.0% |
| Renal Impairment |
4.0% |
| Drug Interaction |
3.6% |
| Headache |
3.6% |
| Lower Respiratory Tract Infection |
3.6% |
| Pain |
3.6% |
| Thrombocytopenia |
3.6% |
| Cough |
3.1% |
| Drug Ineffective |
3.1% |
|
| Interacting |
| Hiv Infection |
66.7% |
| Asthma |
33.3% |
|
| Labelled Drug-drug Interaction Medication Error |
50.0% |
| Muscle Atrophy |
50.0% |
|
